cefalotin

Small moleculeapproved

Approved

Dec 18, 1974

Cephalothin is a first generation, semisynthetic analogue of natural cephalosporin antibiotic. The in-vitro bactericidal action of Cephalothin results from inhibition of cell-wall synthesis. In general, Cephalothin has higher activity against Gram positive than Gram negative organisms. Cephalothin is primarily indicated in conditions like bone and joint infection, genitourinary tract infections, respiratory tract infections, soft tissue and skin infections and others. The severe or irreversible adverse effects of Cephalothin, which give rise to further complications, include nephrotoxicity, hemolytic anemia. Cephalothin produces potentially life-threatening effects, which include anaphylaxis, serum sickness syndrome. The symptomatic adverse reactions produced by Cephalothin are: rashes, urticaria, allergic reactions, thrombophlebitis, pain at injection site. Co-administration of diuretics, such as furanthril, ethacrynic acid and nephrotoxic antibiotics may increase the risk of renal damage. Reciprocal inactivation could be observed during in vitro mixing of Cephalothin with aminoglycosides. — NCATS

Chemistry & pharmacology

Loading structure…

SMILES

CC(=O)OCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3cccs3)[C@H]2SC1
Mol. weight
396.45 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Discontinued

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • 38253
  • 38253
  • 3-acetoxymethyl-7-(2-thienylacetamido)-3-cephem-4-carboxylic acid
  • 3-acetoxymethyl-7-(2-thienylacetamido)-3-cephem-4-carboxylic acid
  • 7-(2-thienylacetamido)cephalosporanic acid
  • 7-(2-thienylacetamido)cephalosporanic acid
  • 7-(2'-thienylacetamido)cephalosporanic acid
  • 7-(2'-thienylacetamido)cephalosporanic acid
  • 7-(thiophene-2-acetamido)cephalosporin
  • 7-(thiophene-2-acetamido)cephalosporin
  • averon
  • averon
  • cefalothin
  • cefalothin
  • cefalotin
  • cefalotin
  • cefalotin
  • cefalotin
  • cefalotin
  • cefalotin
  • cefalotina
  • cefalotina
  • cefalotine
  • cefalotine
  • cefalotin sodium
  • cefalotin sodium
  • cefalotin sodium
  • cefalotin sodium
  • cefalotin sodium
  • cefalotin sodium
  • cefalotinum
  • cefalotinum
  • cephalothin
  • cephalothin
  • cephalothin
  • cephalothin
  • cephalothin
  • cephalothin
  • cephalothin sodium
  • cephalothin sodium
  • cephalothin sodium
  • cephalothin sodium
  • cephalothin sodium salt
  • cephalotin
  • cephalotin
  • cephalotin
  • cet
  • cet
  • keflin
  • keflin
  • keflin
  • seffin
  • seffin
  • synclotin
  • synclotin
  • toricelocin
  • toricelocin

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06430736Phase 2Jul 1, 2024University of Bern
NCT03671681N/ANov 30, 2018Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
NCT03324854N/AJul 1, 2016Universidad Autonoma de San Luis Potosi
NCT03877289Phase 4Oct 31, 2008University of Calgary
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaAcademic/Hospital1112018
Universidad Autonoma de San Luis PotosiAcademic/Hospital1112016
University of BernAcademic/Hospital1112024
University of CalgaryAcademic/Hospital1112008
4 organizations
Page 1 / 1

Marketing (10)

OrganizationOrg typeRelationshipDate
AbbottFor profitMKTG
AbraxisFor profitMKTG
BaxaltaFor profitMKTGJan 31, 1984
BaxterFor profitMKTGJan 31, 1984
Bristol-MyersFor profitMKTG
Eli LillyFor profitNDA
Eli LillyFor profitSYNDec 18, 1974
Eli LillyFor profitMKTGSep 10, 1985
GlaxoSmithKlineFor profitMKTG
International MedicationFor profitMKTG